SG11201903099QA - Wt1 targeting dna vaccine for combination therapy - Google Patents
Wt1 targeting dna vaccine for combination therapyInfo
- Publication number
- SG11201903099QA SG11201903099QA SG11201903099QA SG11201903099QA SG11201903099QA SG 11201903099Q A SG11201903099Q A SG 11201903099QA SG 11201903099Q A SG11201903099Q A SG 11201903099QA SG 11201903099Q A SG11201903099Q A SG 11201903099QA SG 11201903099Q A SG11201903099Q A SG 11201903099QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- treatment
- pct
- combination therapy
- gitr
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108020004414 DNA Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 abstract 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 2
- 102000053602 DNA Human genes 0.000 abstract 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 abstract 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 abstract 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 abstract 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 abstract 2
- 102000017578 LAG3 Human genes 0.000 abstract 2
- 101150030213 Lag3 gene Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- -1 OX-40 Proteins 0.000 abstract 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 abstract 2
- 241000607142 Salmonella Species 0.000 abstract 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 abstract 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 208000008383 Wilms tumor Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 May 2018 (11.05.2018) omits I Elo 011111 00101011101110#01I (10) International Publication Number WO 2018/083209 Al WIPO I PCT (51) International Patent Classification: A61K 39/00 (2006.01) C07K 16/28 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) PCT/EP2017/078124 (22) International Filing Date: 03 November 2017 (03.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16197322.7 04 November 2016 (04.11.2016) EP (71) Applicant: VAXIMM AG [CH/CH]; Hochbergerstrasse 60c, 4057 Basel (CH). (72) Inventor: LUBENAU, Heinz; An der Eselshaut 12, 67435 Neustadt an der Weinstrasse (DE). (74) Agent: WALLINGER RICKER SCHLOTTER TOST- MANN PATENT- UND RECHTSANWALTE PART- NERSCHAFT MBB; ZweibriickenstraBe 5-7, 80331 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: WT1 TARGETING DNA VACCINE FOR COMBINATION THERAPY (57) : The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding Wilms' Tumor Protein (WT1), for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one checkpoint inhibitor, particularly selected from at least one antibody against PD-1, PD-L1,CTLA-4, IDO, OX-40, GITR, TIM-3, and LAG-3.The present invention further relates to a pharmaceutical composition com- prising an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding WT1 for use in the treatment of cancer, wherein the treatment further comprises the administration of at least one checkpoint inhibitor, particularly selected from at least one antibody against PD-1, PD-L1,CTLA-4, IDO, OX-40, GITR, TIM-3, and LAG-3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16197322 | 2016-11-04 | ||
| PCT/EP2017/078124 WO2018083209A1 (en) | 2016-11-04 | 2017-11-03 | Wt1 targeting dna vaccine for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903099QA true SG11201903099QA (en) | 2019-05-30 |
Family
ID=57249707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903099QA SG11201903099QA (en) | 2016-11-04 | 2017-11-03 | Wt1 targeting dna vaccine for combination therapy |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230158133A1 (en) |
| EP (1) | EP3534935A1 (en) |
| JP (1) | JP2019533698A (en) |
| KR (1) | KR20190082227A (en) |
| CN (1) | CN109906087A (en) |
| AU (1) | AU2017353432A1 (en) |
| BR (1) | BR112019009003A2 (en) |
| CA (1) | CA3041375A1 (en) |
| IL (1) | IL265684A (en) |
| MX (1) | MX2019005212A (en) |
| RU (1) | RU2019112977A (en) |
| SG (1) | SG11201903099QA (en) |
| WO (1) | WO2018083209A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114980871A (en) | 2020-01-13 | 2022-08-30 | 万科斯蒙股份有限公司 | Salmonella-based DNA vaccine in combination with antibiotics |
| EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
| KR20230066249A (en) * | 2021-11-05 | 2023-05-15 | 전남대학교산학협력단 | A Pharmaceutical composition for preventing or treating of cancer comprising Salmonella strain and immune check point inhibitor as an active ingredient |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029315B2 (en) * | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
| WO2012149364A1 (en) * | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| NO337687B1 (en) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspectral camera and method of recording hyperspectral data |
| SG11201500054QA (en) * | 2012-07-05 | 2015-03-30 | Vaximm Ag | Dna vaccine for use in pancreatic cancer patients |
| CN107252485A (en) * | 2013-04-03 | 2017-10-17 | Ibc药品公司 | For inducing the combination treatment to the immune response of disease |
| HUE038861T2 (en) * | 2013-04-25 | 2018-12-28 | Vaximm Ag | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
| AU2014365900B2 (en) * | 2013-12-18 | 2020-04-09 | Vaximm Gmbh | Novel MSLN targeting DNA vaccine for cancer immunotherapy |
| US10975112B2 (en) * | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
| DK3310379T3 (en) * | 2015-06-18 | 2019-12-16 | Vaximm Ag | VEGFR-2 TARGETING DNA VACCINE FOR COMBINATION THERAPY |
| US20180153976A1 (en) * | 2015-06-18 | 2018-06-07 | Vaximm Ag | Novel cmv pp65 targeting dna vaccine for cancer immunotherapy |
-
2017
- 2017-11-03 BR BR112019009003A patent/BR112019009003A2/en not_active Application Discontinuation
- 2017-11-03 EP EP17797909.3A patent/EP3534935A1/en not_active Withdrawn
- 2017-11-03 CN CN201780068135.3A patent/CN109906087A/en active Pending
- 2017-11-03 AU AU2017353432A patent/AU2017353432A1/en not_active Abandoned
- 2017-11-03 SG SG11201903099QA patent/SG11201903099QA/en unknown
- 2017-11-03 US US16/347,551 patent/US20230158133A1/en not_active Abandoned
- 2017-11-03 WO PCT/EP2017/078124 patent/WO2018083209A1/en unknown
- 2017-11-03 MX MX2019005212A patent/MX2019005212A/en unknown
- 2017-11-03 RU RU2019112977A patent/RU2019112977A/en not_active Application Discontinuation
- 2017-11-03 CA CA3041375A patent/CA3041375A1/en not_active Abandoned
- 2017-11-03 JP JP2019523035A patent/JP2019533698A/en active Pending
- 2017-11-03 KR KR1020197014109A patent/KR20190082227A/en unknown
-
2019
- 2019-03-27 IL IL265684A patent/IL265684A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019112977A (en) | 2020-12-04 |
| EP3534935A1 (en) | 2019-09-11 |
| CA3041375A1 (en) | 2018-05-11 |
| MX2019005212A (en) | 2019-06-20 |
| CN109906087A (en) | 2019-06-18 |
| BR112019009003A2 (en) | 2019-07-16 |
| IL265684A (en) | 2019-05-30 |
| KR20190082227A (en) | 2019-07-09 |
| JP2019533698A (en) | 2019-11-21 |
| US20230158133A1 (en) | 2023-05-25 |
| WO2018083209A1 (en) | 2018-05-11 |
| AU2017353432A1 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 |